How big is UroGen Pharma Ltd.?

As of Jun 18, UroGen Pharma Ltd. has a market capitalization of 610.46 million and reported net sales of 91.87 million with a net profit of -138.42 million over the latest four quarters. Shareholder's funds are at -8.80 million, and total assets amount to 285.71 million.

As of Jun 18, UroGen Pharma Ltd. has a market capitalization of 610.46 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 91.87 million, while the sum of net profit for the same period is -138.42 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds at -8.80 million and total assets amounting to 285.71 million.

What does UroGen Pharma Ltd. do?

UroGen Pharma Ltd. is an Israel-based biopharmaceutical company focused on developing treatments for cancers and urologic diseases. As of March 2025, it has a market cap of $610.46 million, with net sales of $20 million and a net loss of $44 million.

Overview: <BR>UroGen Pharma Ltd. is an Israel-based biopharmaceutical company engaged in building solutions for cancers and urologic diseases within the Pharmaceuticals & Biotechnology industry, classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Sales: 20 Million (Quarterly Results - Mar 2025) <BR>Net Profit: -44 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 610.46 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 1.58 <BR>Return on Equity: 297.97% <BR>Price to Book: -13.14<BR><BR>Contact Details: <BR>Address: 9 Ha'ta'asiya St, RA'ANANA None: 4365007 <BR>Tel: ['972 9 7707601']

Should I buy, sell or hold UroGen Pharma Ltd.?

Who are in the management team of UroGen Pharma Ltd.?

As of March 2022, UroGen Pharma Ltd.'s management team includes Dr. Arie Belldegrun (Independent Chairman), Ms. Elizabeth Barrett (President and CEO), and several Independent Directors: Ms. Cynthia Butitta, Dr. Fred Cohen, Ms. Kathryn Falberg, Dr. Stuart Holden, and Mr. Ran Nussbaum. They oversee the company's strategic direction and operations.

As of March 2022, the management team of UroGen Pharma Ltd. includes the following individuals:<BR><BR>- Dr. Arie Belldegrun, who serves as the Independent Chairman of the Board.<BR>- Ms. Elizabeth Barrett, who is the President, Chief Executive Officer, and a Director.<BR>- Ms. Cynthia Butitta, who is an Independent Director.<BR>- Dr. Fred Cohen, who is also an Independent Director.<BR>- Ms. Kathryn Falberg, another Independent Director.<BR>- Dr. Stuart Holden, who serves as an Independent Director.<BR>- Mr. Ran Nussbaum, who is an Independent Director.<BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Is UroGen Pharma Ltd. overvalued or undervalued?

As of November 9, 2020, UroGen Pharma Ltd. is considered risky and overvalued due to negative valuation ratios, including a Price to Book Value of -7.31 and a P/E ratio of -6.39, despite a strong year-to-date return of 77.18%.

As of 9 November 2020, UroGen Pharma Ltd. moved from does not qualify to risky, indicating a significant downgrade in its valuation outlook. The company appears to be overvalued, given its negative valuation ratios, including a Price to Book Value of -7.31 and an EV to EBITDA of -2.50. Furthermore, its EV to Sales ratio stands at 2.90, which is concerning for a company in the pharmaceuticals and biotechnology sector.<BR><BR>In comparison to its peers, UroGen Pharma Ltd. has a P/E ratio of -6.39, while Avidity Biosciences, Inc. and Janux Therapeutics, Inc. have P/E ratios of -13.56 and -14.22, respectively, indicating that UroGen is less negatively valued but still in a precarious position. Despite a strong year-to-date return of 77.18% compared to the S&P 500's 12.22%, the long-term performance shows a decline of 16.10% over five years, which raises concerns about its sustainability.

Is UroGen Pharma Ltd. technically bullish or bearish?

As of October 31, 2025, UroGen Pharma Ltd. has shifted to a bullish trend, supported by positive moving averages and Bollinger Bands, despite a mildly bearish MACD signal, and has outperformed the S&P 500 with an 86.01% year-to-date return compared to 16.30%.

As of 31 October 2025, the technical trend for UroGen Pharma Ltd. has changed from mildly bullish to bullish. The current stance is bullish, supported by bullish signals from the daily moving averages and Bollinger Bands on both weekly and monthly time frames. However, the MACD shows a mildly bearish signal on the weekly, indicating some caution. <BR><BR>In terms of performance, UroGen has significantly outperformed the S&P 500 year-to-date with a return of 86.01% compared to the S&P 500's 16.30%. Over the past year, the stock also shows strong performance at 62.38% against the S&P 500's 19.89%.